Cassava Sciences, Inc.(SAVA)Earnings, Financials & Key Ratios
SAVA•NASDAQ
$1.96
$94M mkt cap·Price updated Apr 24, 2026
AboutCassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Show more
- Revenue$0
- EBITDA-$140M-34.4%
- Net Income-$24M+75.0%
- EPS (Diluted)-0.52+77.6%
- ROE-17.19%+67.7%
- ROIC-634.06%-71.5%
SAVA Key Insights
Cassava Sciences, Inc. (SAVA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 11.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SAVA Price & Volume
Cassava Sciences, Inc. (SAVA) stock price & volume — 10-year historical chart
Loading chart...
SAVA Growth Metrics
Cassava Sciences, Inc. (SAVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-500.27%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-58.7%
Return on Capital
10 Years-47.81%
5 Years-44.26%
3 Years-63.7%
Last Year-99.87%
SAVA Recent Earnings
Cassava Sciences, Inc. (SAVA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)
Q4 2025Latest
Nov 12, 2025EPS
$0.22
Est $0.27
+18.5%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.18
Revenue
—
Q2 2025
May 8, 2025EPS
$0.48
Revenue
—
Q2 2025
Mar 3, 2025EPS
$0.57
Est $0.68
+16.2%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.22vs $0.27+18.5% | — |
| Q3 2025 | Aug 14, 2025 | $0.18 | — |
| Q2 2025 | May 8, 2025 | $0.48 | — |
| Q2 2025 | Mar 3, 2025 | $0.57vs $0.68+16.2% | — |
Based on last 12 quarters of dataView full earnings history →
SAVA Peer Comparison
Cassava Sciences, Inc. (SAVA) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ATNM | 38.68M | 1.24 | -0.98 | -100% | -384.43% | -151.67% | 0.05 | |
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 ACIU | 302.27M | 2.97 | -3.31 | -86.92% | -19.69% | -101.6% | 0.10 | |
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare SAVA vs Peers
Cassava Sciences, Inc. (SAVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SAVA Income Statement
Cassava Sciences, Inc. (SAVA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 58K | 68K | 69K | 1.57M | 3.05M | 0 | 68.03M | 89.42M | 0 | 39.51M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -58K▲ 0% | -68K▼ 17.2% | -69K▼ 1.5% | -1.57M▼ 2172.5% | -3.05M▼ 94.7% | 0▲ 100.0% | -68.03M▲ 0% | -89.42M▼ 31.4% | 0▲ 100.0% | -39.51M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -28.89% | -17.24% | -1.47% | -2172.46% | -94.71% | 100% | - | -31.44% | 100% | - |
| Operating Expenses | 14.96M | 11.95M | 6.66M | 3.39M | 3.39M | 32.87M | 11.99M | 16.53M | 141.45M | 71.81M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.78M | 4.33M | 3.69M | 3.39M | 3.74M | 8.05M | 11.99M | 16.53M | 71.81M | 25.54M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 9.18M | 7.62M | 2.97M | 6.3M | 7.25M | 24.81M | 68.93M | 89.42M | 69.64M | 43.27M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -6.3M | -7.6M | 0 | -68.93M | -89.42M | 0 | -1000K |
| Operating Income | -14.96M▲ 0% | -11.95M▲ 20.1% | -6.66M▲ 44.2% | -4.96M▲ 25.6% | -6.45M▼ 30.0% | -32.87M▼ 409.9% | -80.02M▼ 143.5% | -105.96M▼ 32.4% | -141.45M▼ 33.5% | -111.33M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -5.32% | 20.11% | 44.25% | 25.56% | -29.99% | -409.9% | -143.46% | -32.41% | -33.49% | - |
| EBITDA | -14.9M | -11.88M | -6.59M | -4.9M | -6.42M | -32.33M | -78.72M | -104.43M | -140.31M | -110.43M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -5.24% | 20.26% | 44.51% | 25.66% | -31.08% | -403.33% | -143.46% | -32.66% | -34.37% | 17.3% |
| D&A (Non-Cash Add-back) | 58K | 68K | 69K | 58K | 22K | 534K | 1.3M | 1.53M | 1.13M | 898K |
| EBIT | -14.85M | -11.91M | -6.56M | -4.96M | -6.79M | -32.87M | -80.02M | -105.96M | -142.28M | -66.07M |
| Net Interest Income | 0 | 0 | 0 | 328K | 112K | 49K | 2.78M | 7.83M | 8.51M | 5.45M |
| Interest Income | 107K | 38K | 105K | 328K | 112K | 49K | 2.78M | 7.83M | 8.51M | 5.45M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 107K | 38K | 105K | 328K | 112K | 483K | 3.77M | 8.74M | 117.1M | 5.29M |
| Pretax Income | -14.85M▲ 0% | -11.91M▲ 19.8% | -6.56M▲ 45.0% | -4.63M▲ 29.4% | -6.33M▼ 36.8% | -32.38M▼ 411.3% | -76.25M▼ 135.4% | -97.22M▼ 27.5% | -24.34M▲ 75.0% | -106.03M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -107K | -38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.72% | 0.32% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -14.85M▲ 0% | -11.91M▲ 19.8% | -6.56M▲ 45.0% | -4.63M▲ 29.4% | -6.33M▼ 36.8% | -32.38M▼ 411.3% | -76.25M▼ 135.4% | -97.22M▼ 27.5% | -24.34M▲ 75.0% | -106.03M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -4.98% | 19.79% | 44.95% | 29.37% | -36.77% | -411.29% | -135.44% | -27.5% | 74.96% | -500.27% |
| Net Income (Continuing) | -14.85M | -11.91M | -6.56M | -4.63M | -6.33M | -32.38M | -76.25M | -97.22M | -24.34M | -106.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.28▲ 0% | -1.82▲ 20.2% | -0.61▲ 66.5% | -0.24▲ 60.7% | -0.22▲ 8.3% | -0.81▼ 268.2% | -1.80▼ 122.2% | -2.32▼ 28.9% | -0.52▲ 77.6% | -2.20▲ 0% |
| EPS Growth % | -5.56% | 20.18% | 66.48% | 60.66% | 8.33% | -268.18% | -122.22% | -28.89% | 77.59% | -58.7% |
| EPS (Basic) | -2.28 | -1.82 | -0.61 | -0.24 | -0.22 | -0.81 | -1.80 | -2.32 | -0.53 | - |
| Diluted Shares Outstanding | 6.52M | 6.54M | 10.68M | 17.41M | 26.11M | 39.41M | 40.2M | 41.93M | 46.6M | 48.29M |
| Basic Shares Outstanding | 6.52M | 6.54M | 10.68M | 17.41M | 26.11M | 39.41M | 40.2M | 41.93M | 46.33M | 48.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SAVA Balance Sheet
Cassava Sciences, Inc. (SAVA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 19.07M | 10.66M | 20.04M | 23.35M | 93.99M | 244.48M | 211.23M | 129.63M | 136.53M | 108.91M |
| Cash & Short-Term Investments | 18.71M | 10.48M | 19.81M | 23.08M | 93.51M | 233.44M | 201.01M | 121.14M | 128.57M | 106.08M |
| Cash Only | 18.71M | 10.48M | 19.81M | 23.08M | 93.51M | 233.44M | 201.01M | 121.14M | 128.57M | 106.08M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 962K | 947K | 817K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 356K | 184K | 233K | 268K | 31K | 10.38M | 160K | 6.78M | 6.21M | 107K |
| Total Non-Current Assets | 232K | 168K | 99K | 137K | 306K | 22.3M | 23.61M | 22.03M | 21M | 20.82M |
| Property, Plant & Equipment | 300K | 200K | 100K | 137K | 306K | 20.83M | 22.99M | 21.85M | 20.96M | 20.82M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 1.07M | 622K | 176K | 37K | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -68K | -32K | -1K | 0 | 0 | 399K | 0 | 0 | 0 | 0 |
| Total Assets | 19.3M▲ 0% | 10.83M▼ 43.9% | 20.14M▲ 85.9% | 23.49M▲ 16.6% | 94.3M▲ 301.5% | 266.78M▲ 182.9% | 234.83M▼ 12.0% | 151.66M▼ 35.4% | 157.53M▲ 3.9% | 129.73M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -39.53% | -43.89% | 85.94% | 16.62% | 301.52% | 182.91% | -11.98% | -35.42% | 3.87% | -92.06% |
| Total Current Liabilities | 665K | 1.13M | 511K | 1.39M | 1.86M | 12.53M | 7.06M | 14.2M | 11.75M | 48.05M |
| Accounts Payable | 303K | 424K | 294K | 453K | 911K | 7.13M | 4.02M | 10.57M | 7.65M | 46.09M |
| Days Payables Outstanding | 1.91K | 2.28K | 1.56K | 105.45 | 108.91 | - | 21.55 | 43.16 | - | 241.94 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 27K | 399K | 156K | 67K | 177K | 631K | 662K | 3.42M | 45K | 588K |
| Current Ratio | 28.68x | 9.42x | 39.22x | 16.83x | 50.40x | 19.51x | 29.91x | 9.13x | 11.62x | 11.62x |
| Quick Ratio | 28.68x | 9.42x | 39.22x | 16.83x | 50.40x | 19.51x | 29.91x | 9.13x | 11.62x | 11.62x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 303K | 424K | 294K | 0 | 235K | 333K | 232K | 0 | 79K | 119K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 235K | 139K | 35K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 194K | 197K | 0 | 79K | 356K |
| Total Liabilities | 665K | 1.13M | 511K | 1.39M | 2.1M | 12.87M | 7.29M | 14.2M | 11.83M | 48.16M |
| Total Debt | 0 | 0 | 0 | 90K | 293K | 236K | 139K | 0 | 0 | 0 |
| Net Debt | -18.71M | -10.48M | -19.81M | -22.99M | -93.21M | -233.2M | -200.88M | -121.14M | -128.57M | -106.08M |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.96x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 18.64M▲ 0% | 9.7M▼ 48.0% | 19.63M▲ 102.4% | 22.1M▲ 12.6% | 92.2M▲ 317.2% | 253.91M▲ 175.4% | 227.54M▼ 10.4% | 137.47M▼ 39.6% | 145.7M▲ 6.0% | 81.57M▲ 0% |
| Equity Growth % | -36.54% | -47.96% | 102.37% | 12.59% | 317.21% | 175.4% | -10.39% | -39.58% | 5.99% | -36.14% |
| Book Value per Share | 2.86 | 1.48 | 1.84 | 1.27 | 3.53 | 6.44 | 5.66 | 3.28 | 3.13 | 1.69 |
| Total Shareholders' Equity | 18.64M | 9.7M | 19.63M | 22.1M | 92.2M | 253.91M | 227.54M | 137.47M | 145.7M | 81.57M |
| Common Stock | 46K | 7K | 17K | 22K | 35K | 40K | 42K | 42K | 48K | 48K |
| Retained Earnings | -145.49M | -157.4M | -163.96M | -168.59M | -174.92M | -207.31M | -283.55M | -380.77M | -405.11M | -483.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -700K | -800K | -900K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SAVA Cash Flow Statement
Cassava Sciences, Inc. (SAVA) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.23M | -8.24M | -4.77M | -2.51M | -5.38M | -30.2M | -77.51M | -82.03M | -116.93M | -116.93M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -35.14% | 32.67% | 42.09% | 47.3% | -114.08% | -461.06% | -156.7% | -5.82% | -42.55% | 5.08% |
| Net Income | -14.85M | -11.91M | -6.56M | -4.63M | -6.33M | -32.38M | -76.25M | -97.22M | -24.34M | -106.03M |
| Depreciation & Amortization | 58K | 68K | 69K | 58K | 22K | 534K | 1.3M | 1.53M | 1.13M | 829K |
| Stock-Based Compensation | 4.33M | 2.97M | 2.39M | 1.3M | 988K | 1.76M | 2.07M | 4.59M | 16.29M | 19.95M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 3.39M | -8.12M | 0 | 0 | 0 |
| Other Non-Cash Items | -8K | -2K | 2.66M | 0 | -346K | -3.39M | 8.12M | 0 | -108.18M | 0 |
| Working Capital Changes | -1.77M | 635K | -670K | 763K | 288K | -104K | -4.63M | 9.08M | -1.83M | 1.48M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -711K | 129K | -130K | 159K | 458K | 6.21M | -3.45M | 6.9M | -2.92M | -6.46M |
| Cash from Investing | -2.17M | 2.1M | 0 | -18K | 360K | -22.21M | -2.71M | -414K | -103K | -137K |
| Capital Expenditures | -75K | 0 | 0 | -18K | 0 | -22.21M | -2.71M | -414K | -103K | -137K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -2.09K | 2.1K | 0 | 0 | 360K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -284K | 0 | 14.1M | 5.81M | 75.45M | 192.34M | 47.8M | 2.56M | 124.47M | 1.01M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.01M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -60K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -284K | 0 | 0 | 0 | 256K | 2.52M | 475K | 0 | 0 | 0 |
| Net Change in Cash | -14.68M▲ 0% | -6.14M▲ 58.2% | 9.33M▲ 252.0% | 3.27M▼ 64.9% | 70.42M▲ 2051.0% | 139.93M▲ 98.7% | -32.42M▼ 123.2% | -79.88M▼ 146.4% | 7.44M▲ 109.3% | -82.9M▲ 0% |
| Free Cash Flow | -12.31M▲ 0% | -8.24M▲ 33.1% | -4.77M▲ 42.1% | -2.53M▲ 46.9% | -5.38M▼ 112.6% | -52.41M▼ 873.8% | -80.23M▼ 53.1% | -82.44M▼ 2.8% | -117.03M▼ 42.0% | -83.91M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -33.1% | 33.08% | 42.09% | 46.92% | -112.56% | -873.8% | -53.07% | -2.76% | -41.96% | -7.48% |
| FCF per Share | -1.89 | -1.26 | -0.45 | -0.15 | -0.21 | -1.33 | -2.00 | -1.97 | -2.51 | -2.51 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.69x | 0.73x | 0.54x | 0.85x | 0.93x | 1.02x | 0.84x | 4.80x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SAVA Key Ratios
Cassava Sciences, Inc. (SAVA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -61.87% | -84.07% | -44.72% | -22.2% | -11.08% | -18.71% | -31.67% | -53.27% | -17.19% | -95.77% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -250.25% | -253.35% | -369.66% | -634.06% | -634.06% |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | - | - | 0.00x |
| FCF Conversion | 0.82x | 0.69x | 0.73x | 0.54x | 0.85x | 0.93x | 1.02x | 0.84x | 4.80x | 0.79x |
SAVA Frequently Asked Questions
Cassava Sciences, Inc. (SAVA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cassava Sciences, Inc. (SAVA) grew revenue by 0.0% over the past year. Growth has been modest.
Cassava Sciences, Inc. (SAVA) reported a net loss of $106.0M for fiscal year 2024.
Dividend & Returns
Cassava Sciences, Inc. (SAVA) has a return on equity (ROE) of -17.2%. Negative ROE indicates the company is unprofitable.
Cassava Sciences, Inc. (SAVA) had negative free cash flow of $83.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More SAVA
Cassava Sciences, Inc. (SAVA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates